Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
RapidPulse, Inc · NCT06029491
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–85 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 170
- US sites recruiting
- 13
- Study start
- March 27, 2025
- Record last updated
- October 21, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participation in the trial is for 90 days.
Being studied: RapidPulseTM Aspiration System
Conditions: Acute Ischemic Stroke
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 18 to 85 years
- Clinical diagnosis of acute ischemic stroke with NIH Stroke Scale (NIHSS) score ≥ 6
- Able to be treated within 8 hours of symptom onset or last known normal (LKN)
- Able to be treated within 120 minutes from the time of the qualifying baseline CT/MR image
- Pre-morbid Modified Rankin Scale (mRS) score 0-1
- Angiographic confirmation of large vessel occlusion (LVO) in the anterior (intracranial ICA or MCA M1 or M2 segments) or posterior circulation (vertebral or basilar arteries) as confirmed by digital subtraction angiography (DSA) irrespective of IV thrombolysis administration
- Candidate to receive treatment with ADAPT technique (Direct Aspiration First-Pass Technique)
Exclusion Criteria
- Intracranial Hemorrhage (ICH)
- Significant mass effect and/or midline shift
- Alberta Stroke Program Early CT Score (ASPECTS) \<6 or (PC-ASPECTS \<8 on CT angiography source images or DWI MRI for posterior circulation stroke)
- Intracranial Atherosclerotic Disease (ICAD)
- Multiple or tandem occlusions
- Life expectancy less than 6 months
Recruiting US locations
Providence Saint John's Medical Foundation
Torrance, CA 90503
Site contact: Jason Tarpley, MD
Yale University
New Haven, CT 06519
Site contact: Charles Matouk, MD
Baptist Health Research Institute
Jacksonville, FL 32207
Site contact: Amin Aghaebrahim, MD
University of South Florida
Tampa, FL 33620
Site contact: Maxim Mokin, MD
Emory University at Grady
Atlanta, GA 30303
Site contact: Jonathan Grossberg, MD
Rush University Medical Center
Chicago, IL 60612
Site contact: Michael Chen, MD
Advocate Aurora Research Institute
Park Ridge, IL 60068
Site contact: Michael Young, MD
State University of Iowa
Iowa City, IA 52242
Site contact: Edgar Samaniego, MD
Washington University
St Louis, MO 63110
Site contact: Arindam Chatterjee, MD
State University of New York at Buffalo
Buffalo, NY 14203
Site contact: Jason Davies, MD
Icahn School of Medicine at Mount Sinai
New York, NY 10029
Site contact: Tomoyoshi Shigematsu, MD
Semmes Murphey Foundation - Baptist Memorial Hospital
Memphis, TN 38120
Site contact: Nitin Goyal, MD
Valley Baptist Medical Center - Harlingen
Harlingen, TX 78550
Site contact: Ameer Hassan, DO
Study contacts (from the official record)
- Cynthia Yang · 9498367402 · cyang@rapidpulsemed.com
Similar studies in California
All neurology studies in California →- RecruitingHealthy volunteersPhase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Eli Lilly and Company
- Location
- Los Alamitos, CA + 7 other US sites
- Eligibility basics
- Ages 30–85
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early…
Bristol-Myers Squibb
- Location
- Anaheim, CA
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Eli Lilly and Company
- Location
- Los Alamitos, CA + 5 other US sites
- Eligibility basics
- Ages 45–85
- RecruitingHealthy volunteersPhase 1/Phase 2
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Ashvattha Therapeutics, Inc.
- Location
- San Francisco, CA + 2 other US sites
- Eligibility basics
- Ages 18–80